On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.

Apr 09, 2019

Media Release

Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off.

Read More

Video - The future of Novartis

Our future is as a leading focused medicines company, powered by data science and advanced therapy platforms. CEO Vas Narasimhan shares our vision.

Vas on Instagram

In Pictures

Alcon lists on the SIX Swiss Exchange and New York Stock Exchange (NYSE)

Novartis CFO Harry Kirsch and Alcon Chairman Mike Ball at the SIX Swiss Exchange in Zürich
Novartis CFO Harry Kirsch and Alcon Chairman Mike Ball at the SIX Swiss Exchange in Zürich.

 NYSE tweeted pictures of the Alcon team in New York

Additional Resources

New Alcon website

Download the Swiss Listing Prospectus (PDF 2.2 MB)

Download the Supplement to the Swiss Listing Prospectus (PDF 0.4 MB)

Download the Alcon 20-F (PDF 2.0 MB)

Download the Form 6-K: Alcon Appoints Senior Leaders in Final Preparation for Spin-off (PDF 0.1 MB)

Download the Form 8937: Basis of Securities (PDF 0.1 MB)